Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading Volume - Time to Buy?

Key Points

• Pharming Group's stock saw a trading volume increase of 28% with 7,617 shares exchanged, despite the stock price dropping 8.5% to $11.16.
• The company's latest earnings report showed an EPS of $0.06, exceeding analysts' expectations, with revenue reaching $93.20 million compared to an expected $70.36 million.
• Institutional investor Silverberg Bernstein Capital Management raised its stake in Pharming Group by 8.6%, now holding approximately 0.08% of the company's stock worth $557,000.

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) shares saw unusually-high trading volume on Tuesday . Approximately 7,617 shares were traded during mid-day trading, an increase of 28% from the previous session's volume of 5,934 shares.The stock last traded at $11.16 and had previously closed at $12.10.

Pharming Group Price Performance

The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.07 and a current ratio of 2.79. The stock has a market capitalization of $798.14 million, a PE ratio of -89.62 and a beta of 0.02. The company's fifty day simple moving average is $10.87 and its two-hundred day simple moving average is $9.65.

Pharming Group (NASDAQ:PHAR - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The company reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.10) by $0.16. Pharming Group had a negative net margin of 2.19% and a negative return on equity of 3.31%. The business had revenue of $93.20 million for the quarter, compared to analyst estimates of $70.36 million. As a group, sell-side analysts predict that Pharming Group N.V. Sponsored ADR will post -0.2 EPS for the current year.

Institutional Investors Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its stake in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) by 8.6% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 52,147 shares of the company's stock after acquiring an additional 4,150 shares during the period. Silverberg Bernstein Capital Management LLC owned approximately 0.08% of Pharming Group worth $557,000 as of its most recent SEC filing. 0.03% of the stock is currently owned by institutional investors and hedge funds.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.